Isabel Paoli - Merck KGaA Chief Strategy Officer, Head of Communications
| MKKGY Stock | USD 32.25 0.18 0.56% |
Executive
Ms. Isabel De Paoli was Chief Strategy Officer and Head of Communications at Merck KGaA with effect from October 1, 2016. She will assume Chief Strategy Officer role in addition to her position as Head of Communications. She joined Merck in August 2006 as Business Development Manager Chemicals and was appointed Head of Strategic Planning Oncology in 2009. Between 2012 and 2015 she was responsible for Group Strategy, establishing the global function and introducing a systematic strategy development process. In 2015 she was appointed as Head of Group Communications. Following her Chemical Engineering studies in Brazil and Hamburg, she began her career as consultant, working for The Boston Consulting Group, from where she moved to private equity firm Permira. since 2016.
| Tenure | 8 years |
| Phone | 49 6151 72 0 |
| Web | https://www.merckgroup.com |
Merck KGaA Management Efficiency
The company has return on total asset (ROA) of 0.0656 % which means that it generated a profit of $0.0656 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1422 %, meaning that it generated $0.1422 on every $100 dollars invested by stockholders. Merck KGaA's management efficiency ratios could be used to measure how well Merck KGaA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Akihiko Okamoto | Recruit Holdings Co | N/A | |
| Toshio Oka | Recruit Holdings Co | N/A | |
| Edeltraud Glaenzer | MERCK Kommanditgesellschaft auf | 62 | |
| Siegfried Karjetta | MERCK Kommanditgesellschaft auf | 63 | |
| Michaela Glenck | MERCK Kommanditgesellschaft auf | N/A | |
| Suguru Tomizuka | Recruit Holdings Co | 51 | |
| Gerhard Bauer | Straumann Holding AG | 62 | |
| Mechthild Auge | MERCK Kommanditgesellschaft auf | N/A | |
| Peter Merck | MERCK Kommanditgesellschaft auf | 51 | |
| Masao Ito | Ono Pharmaceutical Co | N/A | |
| Helga RuebsamenSchaeff | MERCK Kommanditgesellschaft auf | 69 | |
| Wolfgang Becker | Straumann Holding AG | 57 | |
| Helene Roeder | MERCK Kommanditgesellschaft auf | 48 | |
| Oscar Paco | Fresenius SE Co | 44 | |
| Belen Garijo | MERCK Kommanditgesellschaft auf | 57 | |
| Stefanie Lang | Fresenius SE Co | 49 | |
| Katsunori Morio | Ono Pharmaceutical Co | N/A | |
| Gabriele Eismann | MERCK Kommanditgesellschaft auf | 56 | |
| Albrecht Merck | MERCK Kommanditgesellschaft auf | N/A | |
| Shozo Matsuoka | Ono Pharmaceutical Co | 58 | |
| Frank Hemm | Straumann Holding AG | 48 | |
Management Performance
| Return On Equity | 0.14 | |||
| Return On Asset | 0.0656 |
Merck KGaA ADR Leadership Team
Elected by the shareholders, the Merck KGaA's board of directors comprises two types of representatives: Merck KGaA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck KGaA's management team and ensure that shareholders' interests are well served. Merck KGaA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck KGaA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthias Heinzel, CEO Board | ||
| Gerhard Schmitz, Head Accounting | ||
| Stefan Oschmann, Chairman of Executive Board and CEO | ||
| Constantin Fest, Head of Investor Relations | ||
| Michaela Glenck, Member of the Supervisory Board | ||
| Veit Ulshoefer, Member of the Supervisory Board, Employee Representative | ||
| Gabriele Eismann, Member of the Supervisory Board, Employee Representative | ||
| Peter Guenter, CEO Board | ||
| Wolfgang Buechele, Chairman of the Supervisory Board | ||
| Barbara Weiland, Chief Officer | ||
| Belen MD, Chair CEO | ||
| Anke Schenkel, Head of Group Controlling & Risk Management | ||
| Marcus Kuhnert, Member of the Executive Board, CFO | ||
| Siegfried Karjetta, Member of the Supervisory Board | ||
| Alexander Putz, Member of the Supervisory Board, Employee Representative | ||
| Friederike Rotsch, Group Compliance | ||
| Dietmar Oeter, Member of the Supervisory Board, Employee Representative | ||
| Dirk Toepfer, Chief Officer | ||
| Gregor Schulz, Member of the Supervisory Board | ||
| Theo Siegert, Member of the Supervisory Board | ||
| Constantin Birnstiel, Head of Group Communications | ||
| Edeltraud Glaenzer, Member of the Supervisory Board, Employee Representative | ||
| Kai Beckmann, Chief Administrative Officer, Member of the Executive Board | ||
| Helga RuebsamenSchaeff, Member of the Supervisory Board | ||
| Udit Batra, CEO Life Science, Member of the Executive Board | ||
| Michael Fletterich, Vice Chairman of the Supervisory Board, Employee Representative | ||
| Crocifissa Attardo, Member of the Supervisory Board, Employee Representative | ||
| Albrecht Merck, Member of the Supervisory Board | ||
| Mechthild Auge, Member of the Supervisory Board, Employee Representative | ||
| Belen Garijo, CEO Healthcare, Member of the Executive Board | ||
| Walter Galinat, CEO Performance Materials, Member of the Executive Board | ||
| Tobias Thelen, Member of the Supervisory Board | ||
| Isabel Paoli, Chief Strategy Officer, Head of Communications |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Merck KGaA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.14 | |||
| Return On Asset | 0.0656 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 92.22 B | |||
| Shares Outstanding | 2.17 B | |||
| Shares Owned By Institutions | 0.03 % | |||
| Price To Earning | 33.17 X | |||
| Price To Book | 2.75 X | |||
| Price To Sales | 3.86 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck KGaA ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Merck KGaA ADR information on this page should be used as a complementary analysis to other Merck KGaA's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Merck Pink Sheet analysis
When running Merck KGaA's price analysis, check to measure Merck KGaA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck KGaA is operating at the current time. Most of Merck KGaA's value examination focuses on studying past and present price action to predict the probability of Merck KGaA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck KGaA's price. Additionally, you may evaluate how the addition of Merck KGaA to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |